Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Argenica Therapeutics Ltd (AU:AGN)
ASX:AGN
RESEARCH TOOLSreports
Holding AU:AGN?
Track your performance easily
AGN Stock Chart & Stats
Day’s RangeAU$0 - AU$0
52-Week RangeAU$0.35 - AU$0.99
Previous CloseAU$0.75
Volume21.85K
Average Volume (3M)131.00K
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)AU$8.91M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta0.34
Next Earnings
Mar 04, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares OutstandingN/A
10 Day Avg. Volume142,138
30 Day Avg. Volume131,000
Standard Deviation0.21
R-Squared0.05
Alpha0.05
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$1.15Price Target Upside53.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Argenica Therapeutics Ltd News
PremiumCompany Announcements
Argenica Therapeutics Advances Phase 2 Stroke Trial
PremiumCompany Announcements
Argenica’s Clinical Trial Progress and Financial Health
PremiumCompany Announcements
Argenica Therapeutics Gains FDA Designations for ARG-006PremiumCompany Announcements
Argenica Therapeutics Schedules 2024 AGM
PremiumCompany Announcements
Argenica Therapeutics Bolsters Executive Team
PremiumCompany Announcements
Argenica’s ARG-007 Shows Promise in Stroke Treatment
PremiumCompany Announcements
Argenica Therapeutics Welcomes New DirectorPremiumCompany Announcements
Argenica Therapeutics Bolsters Board for GrowthOptions Prices
Currently, No data available
---
Ownership Overview
AGN FAQ
What was Argenica Therapeutics Ltd’s price range in the past 12 months?
Argenica Therapeutics Ltd lowest share price was AU$0.35 and its highest was AU$0.98 in the past 12 months.
What is Argenica Therapeutics Ltd’s market cap?
Currently, no data Available
When is Argenica Therapeutics Ltd’s upcoming earnings report date?
Argenica Therapeutics Ltd’s upcoming earnings report date is Mar 04, 2025 which is in 114 days.
How were Argenica Therapeutics Ltd’s earnings last quarter?
Argenica Therapeutics Ltd released its earnings results on Aug 21, 2024. The company reported -AU$0.039 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.039.
Is Argenica Therapeutics Ltd overvalued?
According to Wall Street analysts Argenica Therapeutics Ltd’s price is currently Undervalued.
Does Argenica Therapeutics Ltd pay dividends?
Argenica Therapeutics Ltd does not currently pay dividends.
What is Argenica Therapeutics Ltd’s EPS estimate?
Argenica Therapeutics Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Argenica Therapeutics Ltd have?
Argenica Therapeutics Ltd has 128,092,850 shares outstanding.
What happened to Argenica Therapeutics Ltd’s price movement after its last earnings report?
Argenica Therapeutics Ltd reported an EPS of -AU$0.039 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.22%.
Which hedge fund is a major shareholder of Argenica Therapeutics Ltd?
Currently, no hedge funds are holding shares in AU:AGN
---
Argenica Therapeutics Ltd Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$1.15 (53.33% Upside)
AU$1.15 (53.33% Upside)
Blogger Sentiment
Bullish
AU:AGN Sentiment 100%
Sector Average 72%
Sector Average 72%
Technicals
SMA
Positive
20 days / 200 days
Momentum
130.76%
12-Months-Change
Fundamentals
Return on Equity
-50.70%
Trailing 12-Months
Asset Growth
71.66%
Trailing 12-Months
Company Description
Argenica Therapeutics Ltd
Argenica Therapeutics Ltd is engaged in the development and commercialization of novel drug candidates. Its lead neuroprotective peptide candidate, ARG007 improves outcomes in pre-clinical stroke models and is in the process of being verified for its safety and toxicology before commencing Phase 1 clinical trials in humans.
---
AGN Stock 12 Month Forecast
Average Price Target
AU$1.15
▲(53.33% Upside)
Technical Analysis
Best Analysts Covering AGN
1 Year
1 Year Success Rate
2/3 ratings generated profit
1 Year Average Return
-0.50%
reiterated a buy rating 7 days ago
Copying Tanushree Jain's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of -0.50% per trade.
---